Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 Lièvre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 66, 3992, 10.1158/0008-5472.CAN-06-0191 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3 Adams, 2011, Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet Oncol, 10.1016/S1470-2045(11)70102-4 Adams, 2009, Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience, Br J Cancer, 100, 251, 10.1038/sj.bjc.6604877 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines), J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Chung, 2005, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol, 23, 1803, 10.1200/JCO.2005.08.037 Köhne, 2002, Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients, Ann Oncol, 13, 308, 10.1093/annonc/mdf034 De Roock, 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, 1812, 10.1001/jama.2010.1535 Tol, 2009, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 360, 563, 10.1056/NEJMoa0808268 Hecht, 2009, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer, J Clin Oncol, 27, 672, 10.1200/JCO.2008.19.8135 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 Peeters, 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J Clin Oncol, 28, 4706, 10.1200/JCO.2009.27.6055 Bokemeyer, 2008, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience, Proc Am Soc Clin Oncol, 26 Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 Tveit, 2011, Proc Am Soc Clin Oncol, 29 Borner, 2008, Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK, Ann Oncol, 19, 1288, 10.1093/annonc/mdn058 Coleman, 2011, Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data, Lancet, 377, 127, 10.1016/S0140-6736(10)62231-3 2009